Press release
Intrahepatic Cholangiocarcinoma Pipeline Insight and Clinical Trial Phases Report | 20+ Companies and 20+ Drugs
DelveInsight's, "Intrahepatic Cholangiocarcinoma Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Intrahepatic Cholangiocarcinoma pipeline landscape. It covers the Intrahepatic Cholangiocarcinoma pipeline drug profiles, including Intrahepatic Cholangiocarcinoma clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report
• DelveInsight's Intrahepatic Cholangiocarcinoma Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Intrahepatic Cholangiocarcinoma treatment.
• The leading Intrahepatic Cholangiocarcinoma Companies include Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences, Siranomics, Instylla, Inc. and others are currently working to improve the Intrahepatic Cholangiocarcinoma treatment landscape.
• Promising Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009 and others.
• The Intrahepatic Cholangiocarcinoma Companies and academics are working to assess challenges and seek opportunities that could influence Intrahepatic Cholangiocarcinoma R&D. The Intrahepatic Cholangiocarcinoma pipeline therapies under development are focused on novel approaches to treat/improve Intrahepatic Cholangiocarcinoma.
Discover the recent breakthroughs happening Intrahepatic Cholangiocarcinoma pipeline landscape and Intrahepatic Cholangiocarcinoma Pipeline Outlook @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Recent Developmental Activities in the Intrahepatic Cholangiocarcinoma Treatment Landscape
• In September 2021, Knight Therapeutics entered into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply to Knight of tafasitamab and pemigatinib, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America.
• In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.
• In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trial in China.
• Relay Therapeutics announced the initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008, an FGFR2-altered intrahepatic cholangiocarcinomain January 2022.
• In May 2021, Kinnate Biopharma Inc. Closes USD 35 Million Series A Financing to Establish a Chinese Joint Venture. The joint venture will pursue the development of KIN-3248 for the Chinese market. KIN-3248 is a Fibroblast Growth Factor Receptors (FGFR) inhibitor candidate for the treatment of patients with intrahepatic cholangiocarcinoma (ICC).
• The Investigational New Drug application for KIN-3248 was cleared by the US FDA on January 18, 2022, and Kinnate anticipates the initiation of a Phase I trial of KIN-3248 in the first half of 2022.
• In 2022, Basilea will continue its activities in oncology in order to ensure project continuity and progression. For derazantinib, the company will focus on continuing the FIDES-01 study in intrahepatic cholangiocarcinoma (iCCA).
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.
There are many factors affecting the Intrahepatic Cholangiocarcinoma prognosis. Find out these Intrahepatic Cholangiocarcinoma Treatment Landscape @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Intrahepatic Cholangiocarcinoma Emerging Drugs
• Derazantinib: Basilea Pharmaceutica
Derazantinib is an orally administered small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family of kinases. Derazantinib is currently in a registrational phase 2 study inIntrahepatic cholangiocarcinoma (iCCA). In January 2019, Basilea reported results from an interim analysis from this study. The efficacy results were encouraging and the analysis also confirmed the safety profile and tolerability of derazantinib observed in previous clinical studies.
• Durvalumab: AstraZeneca
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Intrahepatic Cholangiocarcinoma Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Intrahepatic Cholangiocarcinoma. The companies which have their Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage, i.e. phase II include, Basilea Pharmaceutica.
Learn more about the novel and emerging Intrahepatic Cholangiocarcinoma pipeline therapies and Intrahepatic Cholangiocarcinoma Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Intrahepatic Cholangiocarcinoma Pipeline Report
• Coverage- Global
• Intrahepatic Cholangiocarcinoma Companies- Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences, Siranomics, Instylla, Inc. and others
• Intrahepatic Cholangiocarcinoma pipeline therapies- Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009 and others.
• Intrahepatic Cholangiocarcinoma Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type
Table of Content
1. Introduction
2. Intrahepatic Cholangiocarcinoma Executive Summary
3. Intrahepatic Cholangiocarcinoma: Overview
4. Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
5. Intrahepatic Cholangiocarcinoma Therapeutic Assessment
6. Late Stage Products (Phase II/III)
7. Melphalan/HDS: Delcath Systems
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Derazantinib: Basilea Pharmaceutica
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. RLY-4008: Relay Therapeutics
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Intrahepatic Cholangiocarcinoma Key Companies
20. Intrahepatic Cholangiocarcinoma Key Products
21. Intrahepatic Cholangiocarcinoma- Unmet Needs
22. Intrahepatic Cholangiocarcinoma- Market Drivers and Barriers
23. Intrahepatic Cholangiocarcinoma- Future Perspectives and Conclusion
24. Intrahepatic Cholangiocarcinoma Analyst Views
25. Intrahepatic Cholangiocarcinoma Key Companies
26. Appendix
Dive deep into rich insights for Intrahepatic Cholangiocarcinoma surgery and drugs, visit Intrahepatic Cholangiocarcinoma Emerging Therapies and Companies @ https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intrahepatic Cholangiocarcinoma Pipeline Insight and Clinical Trial Phases Report | 20+ Companies and 20+ Drugs here
News-ID: 2880098 • Views: …
More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…

Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…

Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…

Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Intrahepatic
Intrahepatic Cholangiocarcinoma Pipeline 2025: Latest FDA Approvals, Clinical Tr …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 18+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ Emerging Therapies Ta …
ChatGPT said: The intrahepatic cholangiocarcinoma (iCCA) pipeline is growing steadily, with over 18 companies focused on targeted and immunotherapeutic strategies. Key advances include FGFR2 fusions, IDH1/2 mutations, and HER2 amplifications, driving precision oncology in this aggressive liver cancer. Approvals of FGFR inhibitors like Pemazyre and Truseltiq have advanced biomarker-driven second-line treatments.
DelveInsight's "Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a detailed analysis of the therapeutic development landscape for iCCA, a…
Intrahepatic Cholangiocarcinoma Market Generated Opportunities, Future Scope 202 …
The intrahepatic cholangiocarcinoma market is estimated to be valued at USD 1.10 billion in 2025 and is expected to reach USD 1.90 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
According to the latest research from CoherentMI, the Intrahepatic Cholangiocarcinoma Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough…
Progressive Familial Intrahepatic Cholestasis Pipeline: Promising Therapies Shap …
The treatment landscape for Progressive Familial Intrahepatic Cholestasis (PFIC), a rare and progressive liver disorder, is evolving rapidly, driven by innovative therapies from leading pharmaceutical and biotech companies. Key players such as Mirum Pharmaceuticals and Vivet Therapeutics are advancing therapeutic options focused on addressing the root causes of cholestasis, including bile acid regulation and hepatic transport. These emerging treatments aim to improve liver function, reduce pruritus, and delay the progression…
Transjugular Intrahepatic Portosystemic Shunt (TIPS) Boston Scientific Corporati …
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a minimally invasive procedure used to treat complications of portal hypertension, such as variceal bleeding and refractory ascites. It involves creating a shunt between the portal and hepatic veins, bypassing the liver to reduce portal pressure. TIPS is performed under fluoroscopic guidance by interventional radiologists. It effectively alleviates symptoms and reduces the risk of complications associated with portal hypertension. TIPS is typically reserved for…